Annexon, Inc. · NASDAQ:ANNX
Annexon — 44th Annual J.P. Morgan Healthcare Conference 2026
26 slides from Annexon's conference presentation, Jan 14, 2026
Slide 1: Stopping Neuroinflammation at Its Source
Exhibit 99.1 STOPPING NEUROINFLAMMATION AT ITS SOURCE TH 44 ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX ©2025 Annexon, Inc. All rights reserved
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forwardlo ‐ oking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All st
Slide 3: Unlocking a New Era of Care for Neuroinflammatory Diseases
Unlocking a New Era of Care for Neuroinflammatory Diseases Two Blockbuster Registrational Opportunities 1 ~10M Patients and >$10B Global Market Dry AMD with Geographic Atrophy Guillain-Barré Syndrome A leading cause of blindness in the elderly Most common cause of acute neuromuscular paralysis Vonap
Slide 4: 2026: A Pivotal Year of Potential Significant Value Creation
2026: A Pivotal Year of Potential Significant Value Creation Driving Value From Multiple Late-Stage Assets Clinically Validated Multiple Catalysts Well-positioned for C1q Platform in 2026 Market Development § Next gen targeted § Cash to fund anticipated key § Vonaprument (ANX007) Ph3 immunotherapies
Slide 5: C1q Inhibition Platform Creates Competitive Advantage
C1q Inhibition Platform Creates Competitive Advantage Transformative therapeutic approach halting neuroinflammation at its source to minimize damage Classical Complement Cascade § Proprietary anti-C1q approach yields enhanced efficacy and safety by blocking all classical cascade neuroinflammation AM
Slide 6: Late-Stage Pipeline with Multiple Blockbuster Opportunities
Late-Stage Pipeline with Multiple Blockbuster Opportunities Diverse and informed drug candidates addressing neuroinflammatory diseases for ~10 million patients PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FLAGSHIP PROGRAMS Autoimmune Tanruprubart Guillain‐ Barré Syndrome (GBS) Dry age‐ related macular degene
Slide 7: Annexon Poised to Capture Asymmetric Value Opportunity
Annexon Poised to Capture Asymmetric Value Opportunity Positioned to unlock significant value with multiple late-stage assets Next Generation C1q Inhibition Second Generation C3 Inhibition Pioneering C1q Inhibition First Generation in several diseases C5 Inhibition Pioneered C3 inhibition in GA 4 ~$
Slide 8: Established Leadership with Drug Development through Commercial Depth
Established Leadership with Drug Development through Commercial Depth Ted Yednock, PhD Rick Artis, PhD Jamie Dananberg, MD Chief Innovation Officer Chief Scientific Officer Chief Medical Officer Doug Love President & CEO Jennifer Lew Michael Overdorf, MBA Shikhar Agarwal Chief Financial Officer Chie
Slide 9: Vonaprument: First Potential Treatment to Preserve Vision for Dry AMD with GA
Vonaprument: First Potential Treatment to Preserve Vision for Dry AMD with Geographic Atrophy Shifting Treatment Paradigm in 2026
Slide 10: Geographic Atrophy Remains a Significant Unmet Need
Geographic Atrophy Remains a Significant Unmet Need No approved treatments demonstrating vision preservation WORLDWIDE US EU 8M+ ~1.5M ~2.5M patients affected patients affected patients affected 1 2 3 by GA by GA by GA • Avg. Age of GA Patient: 79 years • GA greatly impacts quality of GA SEVERELY LI
Slide 11: Vonaprument Designed to Stop Vision Loss Prior to Lesion Growth
Vonaprument Designed to Stop Vision Loss Prior to Lesion Growth Targeting C1q, the locus of disease vs. lagging indicator addressed by first generation C3 and C5 inhibitors Vonaprument Protects Eye Structure: Photoreceptor Cells, Synapses & Function (Vision) Lost Prior to RPE in GA (picture of human
Slide 12: Vonaprument Profoundly Protected Central Retinal Structure
ARCHER Vonaprument Profoundly Protected Central Retinal Phase 2 Structure Responsible for Visual Acuity Protection against loss of photoreceptors (neurons) in retina center, the locus of disease CENTRAL 2.0 MM CENTRAL 1.5 MM 0.35 0.35 Sham (n = 25) Sham (n = 22) 0.3 0.3 Vonaprument pooled (n = 36) V
Slide 13: Vonaprument Demonstrated Robust Vision Protection on Multiple Measures
ARCHER Vonaprument Demonstrated Robust Vision Protection Phase 2 on Multiple Measures of Visual Acuity Consistent, dose dependent vision preservation 1 1 BCVA ≥15-LETTER LOSS THROUGH MONTH 12 LLVA ≥15-LETTER LOSS THROUGH MONTH 12 25 25 21.3% 9.8% 5.6% 9.4% 20.3% 7.6% 20 20 15 15 * 10 10 * * * 5 5 16
Slide 14: Monthly Dosing Reduced Risk of Vision Loss by 73% at Month 12
ARCHER Vonaprument Monthly Dosing Reduced Risk of Phase 2 Vision Loss by 73% at Month 12 BCVA ≥15-LETTER LOSS CONFIRMED AT 2 1 CONSECUTIVE VISITS THROUGH MONTH 12 100% EM (n=89) 73% Risk Reduction Vonaprument EM 95% HR (CI) = 0.272 (0.090 to 0.819); Nominal p = 0.0119 90% EOM (n=92) 50% Risk Reducti
Slide 15: Vonaprument Demonstrated Clear On vs. Off-Treatment Vision Protection
ARCHER Vonaprument Demonstrated Clear On vs. Off-Treatment Phase 2 Vision Protection PATIENTS WITH ANY BCVA ≥15-LETTER LOSS FROM BASELINE 30 Off Treatment Sham pooled (n=89) Sham Pooled (n=89) Reinforces on- A V N oX n007 E aprum OM en ( tn E = O 92) M (n=92) 25 treatment drug effect ANX007 EM (n=89
Slide 16: ARCHER II Pivotal Study: Well-Informed Design and Powering
ARCHER II Phase 3 Phase 3 Pivotal Study: Well-Informed Design and Powering Leverages Phase 2 learnings and enriched for patients with higher risk of vision loss Primary analysis: Treatment masked 15 months through 24 months Vonaprument (ANX007) Monthly 5.0 mg/eye N=659 Randomized 2:1 Sham Sites: Nor
Slide 17: Vonaprument Poised to Capture and Drive Immense GA Market
Vonaprument Poised to Capture and Drive Immense GA Market Pursuing vision preservation to drive a fundamental shift in standard of care Lesion-sparing Vision- medicines preservation medicines ~$1.5B 1 >$7B Combined current sales 2 Global peak sales Vonaprument Vision preservation offers enhanced 1st
Slide 18: Tanruprubart: Potential First-in-Class Targeted Therapy for GBS
Tanruprubart: Potential First‐ in‐ Class Targeted Therapy for Guillain‐ Barré Syndrome Delivering for Patients in 2026
Slide 19: GBS: Sudden Neurological Emergency
GBS: Sudden Neurological Emergency No FDA‐ approved therapies IVIg used off‐ label WORLDWIDE INCIDENCE IN US INCIDENCE IN EUROPE ~150K ~8K ~15K 1 3 cases per year cases per year cases per year • Most common cause of acute neuromuscular paralysis • Typically caused by infection, 1,2,3,4,5,6,7 SIGNIFI
Slide 20: GBS Provides a Compelling Market Opportunity
GBS Provides a Compelling Market Opportunity Tanruprubart is first targeted therapy designed to create a new standard of care in GBS BLOCKBUSTER MARKET OPPORTUNITY FOR GBS Tanruprubart • Single infusion halts neuroinflammation • ~90% of treated patients improved by week 1 >90% Patients Treated >23K
Slide 21: Tanruprubart Significantly Reduced Key Markers of Neuroinflammation Within 1 Week
Phase 3 Distinct From IVIg or Placebo, Tanruprubart Significantly & IGOS Reduced Key Markers of Neuroinflammation Within 1 Week REDUCTION OF ACUTE INFLAMMATORY BIOMARKERS WITHIN 1 WEEK Resulted in Rapid Muscle Strength and Motor Function Recovery 21
Slide 22: ~90% of Treated Patients Responded at Week 1
~90% of Treated Patients Responded at Week 1, Translating Phase 3 to >2X Odds of Fully Recovering at Week 26 vs. Placebo 86% OF PATIENTS TREATED WITH ANX005 2½ TIMES MORE TREATED PATIENTS FULLY IMPROVED IN WEEK 1 (10 PTS ON AVG) RECOVER AT WEEK 26 (GBS-DS = 0) MRC Sumscore at Week 1 GBS-DS Through W
Slide 23: Tanruprubart Demonstrated Profound Impact on Measures Most Important
Tanruprubart Demonstrated Profound Impact on Phase 3 Measures Most Important To Patients, HCPs and Payers Helped Patients Achieve Their Independence Sooner versus Placebo Tanruprubart 56 Days 5 30mg/kg : n=79 Walking independently earlier 1 2 31 days earlier , p=0.0211 Placebo 87 Days n=81 Tanruprub
Slide 24: FORWARD Early Experience with Tanruprubart Treatment in EU & US
FORWARD Early Experience with Tanruprubart Treatment in EU & US Study Suggests Rapid and Consistent Effect Across Geographies Example Patient: Moderate to severe FORWARD STUDY Data • Baseline: bed-bound, hospitalized anticipated in 2026 • Treated with tanruprubart within 4 days from onset 1 • Day 8
Slide 25: In Sum, 2026 is a Pivotal Year for Annexon
In Sum, 2026 is a Pivotal Year For Annexon to Unlock a New Era of Care for Neuroinflammatory Diseases and to Drive Immense Value Establishing the first potential Establishing the first potential targeted vision-preserving treatment for GA rapid-acting treatment for GBS Vonaprument (ANX007) Tanruprub
Slide 26: Mission Driven
MISSION DRIVEN helping millions of people impacted by devastating neuroinflammatory diseases to LIVE THEIR BEST LIVES
Annexon — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix